Lingke Pharmaceutical (Hangzhou) Co., Ltd.
 浙ICP备19010130号      Powered by www.300.cn 

Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001

Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001

New
Release time:
2021-12-01 14:59
Abstract:
Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001
Lynk Pharmaceuticals announced the completion of Series B financing of $50 million

Lynk Pharmaceuticals announced the completion of Series B financing of $50 million

Release time:
2021-08-27 14:33
Abstract:
Lynk Pharmaceuticals announced the completion of Series B financing of $50 million
Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002

Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002

Release time:
2021-08-12 15:20
Abstract:
Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003

Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003

Release time:
2021-06-25 20:16
Abstract:
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003